bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis

Marcy-l’Étoile, France – May 13th 2022 – bioMérieux, a world leader in the field of \textit{in vitro} diagnostics, announces the CE marking of its automated tests to diagnose Chikungunya virus (CHIKV) infection on immunoassay instruments of the VIDAS® range.

Chikungunya virus is transmitted to humans by certain mosquitoes. Due to the significant spread of these mosquitoes throughout the world, this infection which was originally present in only tropical regions, has now been described and can be acquired locally in many countries, including recently in temperate climates like North America and Europe.

VIDAS® Anti-CHIKUNGUNYA IgM and Anti-CHIKUNGUNYA IgG are new automated tests intended as an aid in the diagnosis of Chikungunya virus infection.

These serological assays, as recommended by international guidelines\cite{1-3}, can detect Chikungunya infection during the acute phase and into the chronic phase. Their development has been based on methods and technologies from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID).

Used on the VIDAS® family platforms, the VIDAS® Anti-CHIKUNGUNYA IgM and IgG tests provide reliable results with better traceability than existing manual methods. Their performance and accuracy allow the differentiation of this diagnosis from other similar febrile syndromes caused by infections such as dengue or malaria.

Based on single-sample testing and “Load & Go” concepts, the VIDAS® Anti-CHIKUNGUNYA IgM and IgG are easy to use and accessible to all laboratories. Relying on bioMérieux’s expertise in infectious diseases, these serological assays enable clear-cut results with no equivocal zone and an objective interpretation.

“This new VIDAS® CHIKUNGUNYA panel complements the VIDAS® DENGUE solution launched last year. Our offer of immunoassays directed against vector-borne diseases helps improve access to medically important automated diagnostic tests in low- and middle-income countries. The large VIDAS® installed base in these countries allows fast and wide availability of these tests,” added Pierre Boulud, Chief Operating Officer, Clinical Operations, bioMérieux.

ABOUT VIDAS®

Launched 30 years ago, VIDAS® has transformed the field of immunoassays offering laboratories universal access to a simple, automated and robust technology providing fast and reliable results. Today, VIDAS® is still one of the most widely used immunoassay system in clinical laboratories worldwide.

The VIDAS® menu covers a wide range of pathologies, including infectious and chronic diseases and a range of tests dedicated to emergency and critical care. A number of these parameters are part of the bioMérieux full solution to address the global challenges of antimicrobial resistance (AMR) and sepsis. As it enters into its fourth decade, VIDAS® remains a major focus of the bioMérieux immunoassay strategy with ongoing research into new parameters and frequent launches that create value for labs and clinicians, for the benefit of patients.
ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.


bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

CONTACTS

bioMérieux

Investors Relations
Franck Admant
Tel.: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com

Media Relations
Romain Duchez
Tel.: +33 (0)4 78 87 21 99
media@biomerieux.com

Claire Doligez (Image Sept)
Tel.: +33 (0)1 53 70 74 48
cdoligez@image7.fr

REFERENCES